Seven patients with Stage I uterine sarcomas (greater than or equal to 10 mitoses/10 high-power fields) were treated with surgery plus adjuvant vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy in a pilot study conducted at the University of Kentucky Medical Center from 1978 to 1983. Surgery consisted of total abdominal hysterectomy, bilateral salpingo-oophorectomy, and para-aortic lymph node sampling. Chemotherapy was begun within 1 week of surgery, and all patients received at least six monthly courses of VAC. This chemotherapeutic regimen was well-tolerated, and toxicity was minimal. Two patients had recurrent sarcoma, and one of them has died of disease. The remaining five patients are alive and well with no evidence of disease 48 to 73 months after therapy. The recurrence rate of patients with Stage I uterine sarcomas treated with adjuvant VAC chemotherapy was significantly (P less than 0.02) less than that for similar patients treated at this institution (1964-1977) by surgery alone or surgery plus pelvic radiation. These results suggest that primary adjuvant chemotherapy is beneficial in patients with Stage I uterine sarcomas.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19860415)57:8<1451::aid-cncr2820570802>3.0.co;2-yDOI Listing

Publication Analysis

Top Keywords

stage uterine
16
uterine sarcomas
16
patients stage
12
adjuvant vincristine
8
vincristine dactinomycin
8
dactinomycin cyclophosphamide
8
pilot study
8
vac chemotherapy
8
patients
7
surgery
5

Similar Publications

Reproductive Health Among School Employees in Vijayapura, Karnataka.

Cureus

December 2024

Obstetrics and Gynecology, Shri B M Patil Medical College Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura, IND.

Background Cervical cancer typically progresses over 10-20 years, making it a preventable disease and underscoring the importance of screening. In low-resource settings, Papanicolaou (Pap) smears and visual inspection with acetic acid (VIA) serve as primary screening tools. This study was conducted as part of the noncommunicable disease camps organized by the government of Karnataka, India.

View Article and Find Full Text PDF

Mesonephric-like adenocarcinoma (MLA) is a newly recognized type of carcinoma that occurs in the uterus and ovaries. MLA exhibits distinct morphological and immunophenotypical features similar to those of mesonephric carcinoma of the cervix or vagina, with the majority of reported tumors containing mutations. MLA is exceedingly rare and appears to be associated with aggressive clinical behavior.

View Article and Find Full Text PDF

Reichert's membrane (RM) is a basement membrane of gigantic proportions that surrounds the mammalian embryo following implantation. It is part of the parietal yolk sac, which originates from the wall of the preimplantation blastocyst. RM persists from implantation to birth in rodents and analogous structures occur in other mammals, including primates.

View Article and Find Full Text PDF

Objective: Cervical cancer is a common malignancy among women, and radiotherapy remains a primary treatment modality across all disease stages. However, resistance to radiotherapy frequently results in treatment failure, highlighting the need to identify novel therapeutic targets to improve clinical outcomes.

Methods: The expression of molecule interacting with CasL-2 (MICAL2) was confirmed in cervical cancer tissues and cell lines through western blotting (WB) and immunohistochemistry (IHC).

View Article and Find Full Text PDF

: Cervical mesonephric adenocarcinomas (MNACs) are among the rarest neoplasms of the female genital tract. Unlike the majority of cervical cancers, which are predominantly squamous in origin and strongly associated with HPV seropositivity, MNACs are distinct in both histology and pathophysiology. Despite their unique characteristics, MNACs have historically been managed in parallel with squamous cell carcinomas, resulting in a lack of optimised, evidence-based treatment protocols.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!